Theriva Biologics Priced $2.5M Offering with New Warrants At $1.75/Share, Eyes Unmet Cancer Needs
Portfolio Pulse from Benzinga Newsdesk
Theriva Biologics announced a $2.5 million public offering, pricing shares and warrants at $1.75 each. The company aims to address unmet cancer needs with this funding.
September 27, 2024 | 6:55 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Theriva Biologics has priced a $2.5 million public offering at $1.75 per share, including warrants. This move is aimed at funding their cancer therapeutics development.
The offering is likely to provide Theriva Biologics with necessary capital to advance its cancer therapeutics, potentially boosting investor confidence and stock price in the short term. The pricing of shares and warrants at $1.75 suggests a strategic move to attract investment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100